3 High-Yield Dividend Stocks to Buy and Hold
The article discusses three high-yield dividend stocks: Pfizer, Novo Nordisk, and Sanofi. These companies have faced challenges but are worth investing in for the long haul, especially for dividend seekers.
Intelligence analysis by Llama
The article highlights three high-yield dividend stocks that are worth investing in for the long haul. Despite facing challenges, these companies have a strong pipeline of candidates and are expected to make solid clinical and regulatory progress.
Imagine you have a big garden with many different plants. Some of these plants are very good at making medicine, and they help people feel better. The article talks about three special plants that are very good at making medicine and are worth investing in because they give a lot of money back to the people who own them. These plants are called Pfizer, Novo Nordisk, and Sanofi, and they are all very good at making medicine that helps people.
Analysis
A $60B Vote of Confidence
Pfizer, a pharmaceutical leader, has faced several headwinds in recent years, including mediocre financial results and upcoming patent cliffs. However, the company has not suspended or decreased its payouts, and its forward dividend yield is now a juicy 7.1%. Pfizer boasts several products that are posting solid sales growth and should help nudge the top-line in the right direction over the medium term. The list includes Padcev, a cancer medicine, and Abrysvo, a respiratory syncytial virus vaccine. Pfizer's efforts in oncology and weight-loss look particularly promising, and the company should launch brand-new products in these fields to help it overcome the loss of patent exclusivity for medicines like Eliquis, an anticoagulant, and drive long-term growth.
Why Cursor?
Novo Nordisk is best known for its work in the diabetes and weight loss markets, and with good reason. The company remains one of the undisputed leaders in these fields, despite recent setbacks that have sunk its stock price over the past couple of years. Novo Nordisk is well-positioned to bounce back, though. The company boasts a strong pipeline of candidates across its core therapeutic areas. Novo Nordisk's zenagamtide (amycretin) is currently undergoing phase 3 studies -- in a subcutaneous and an oral formulation -- as a potential weight loss treatment in people who are either overweight or obese. It also posted strong phase 2 results, showing statistically significant reductions in blood sugar and weight loss in patients with type 2 diabetes.
The Road Ahead
Sanofi has faced some headwinds recently, including a leadership change and clinical setbacks. The stock has lagged broader equities as a result. However, there remain good reasons to be optimistic about Sanofi's long-term prospects. Here are three of them. First, the company's most important growth driver, Dupixent, is still performing very well. Dupixent is a medicine indicated for the treatment of eczema and COPD; Sanofi shares the rights to this therapy with Regeneron. Dupixent is one of the world's best-selling drugs and is still helping Sanofi post decent sales growth. Second, Sanofi should make solid pipeline progress over the next few years. For instance, the company's frexalimab, an investigational therapy for multiple sclerosis (among other diseases), is undergoing phase 2 and phase 3 clinical trials. Frexalimab posted excellent mid-stage results and could eventually generate well over $1 billion in annual sales at its peak. Sanofi boasts several other promising candidates. Third, the company offers an attractive forward dividend yield of 5.6% and regularly increases its payouts. The dividend is safe despite recent obstacles, and
Key points
- Pfizer has a forward dividend yield of 7.1% and boasts several products that are posting solid sales growth.
- Novo Nordisk has a strong pipeline of candidates across its core therapeutic areas and is well-positioned to bounce back from recent setbacks.
- Sanofi has a attractive forward dividend yield of 5.6% and regularly increases its payouts, making it a great pick for income seekers.
- All three companies have a strong pipeline of candidates and are expected to make solid clinical and regulatory progress over the next few years.
If these companies continue to make progress in their pipeline and clinical trials, their stock prices could jump well before the end of the decade. Additionally, their dividend yields are attractive, and they regularly increase their payouts, making them a great pick for income seekers.
However, there are also some risks associated with investing in these companies. For example, Pfizer's financial results may not bounce back immediately, and Sanofi's leadership change and clinical setbacks may continue to affect its stock price. Additionally, the pharmaceutical industry is highly competitive, and these companies may face challenges from other companies in the market.
